| Virginia J Rieger, | |
|
727 E Brundage Ln Ste L, Sheridan, WY 82801-6280 | |
| (307) 683-0123 | |
| (307) 683-0101 |
| Full Name | Virginia J Rieger |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 24 Years |
| Location | 727 E Brundage Ln Ste L, Sheridan, Wyoming |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932432101 | NPI | - | NPPES |
| 128519000 | Medicaid | WY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OTR-595 (Wyoming) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Little Goose Therapy, Llc | 0941598437 | 4 |
News Archive
A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.
Skinvisible, Inc. the developers of Invisicare, a polymer delivery system that enhances topically applied products, has been granted a comprehensive patent in Australia.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.
Thousands of men, women and children experience family violence each year, according to the U.S. Department of Justice. Traditionally, therapy for violence survivors has predominantly focused on evaluating their trauma and pain. In contrast, a University of Missouri researcher broadens the therapeutic focus to empower survivors through highlighting their resilience, resourcefulness, and ability to overcome adversity.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
› Verified 2 days ago
| Provider Name | Little Goose Therapy, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1609229319 PECOS PAC ID: 0941598437 Enrollment ID: O20161017001480 |
News Archive
A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.
Skinvisible, Inc. the developers of Invisicare, a polymer delivery system that enhances topically applied products, has been granted a comprehensive patent in Australia.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.
Thousands of men, women and children experience family violence each year, according to the U.S. Department of Justice. Traditionally, therapy for violence survivors has predominantly focused on evaluating their trauma and pain. In contrast, a University of Missouri researcher broadens the therapeutic focus to empower survivors through highlighting their resilience, resourcefulness, and ability to overcome adversity.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Virginia J Rieger, 727 E Brundage Ln Ste L, Sheridan, WY 82801-6280 Ph: (307) 683-0123 | Virginia J Rieger, 727 E Brundage Ln Ste L, Sheridan, WY 82801-6280 Ph: (307) 683-0123 |
News Archive
A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.
Skinvisible, Inc. the developers of Invisicare, a polymer delivery system that enhances topically applied products, has been granted a comprehensive patent in Australia.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.
Thousands of men, women and children experience family violence each year, according to the U.S. Department of Justice. Traditionally, therapy for violence survivors has predominantly focused on evaluating their trauma and pain. In contrast, a University of Missouri researcher broadens the therapeutic focus to empower survivors through highlighting their resilience, resourcefulness, and ability to overcome adversity.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
› Verified 2 days ago
Mrs. Kaitlin Jean Wallace, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 918 W Brundage Ln, Sheridan, WY 82801 Phone: 307-673-4420 | |
Ashton Hudspeth-miller, Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 50 W 3rd St, Sheridan, WY 82801 Phone: 307-672-2092 Fax: 307-673-1969 | |
Alexis Leigh Prosinski, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 352 Whitney Ln, Sheridan, WY 82801 Phone: 307-672-5000 | |
Ms. Connie Allmaras, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1898 Fort Road, Vamc, Sheridan, WY 82801 Phone: 307-672-3473 Fax: 307-672-1958 | |
Ms. Clella C Collier, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1898 Fort Rd, Sheridan, WY 82801 Phone: 307-672-3473 Fax: 307-672-1941 | |
Mrs. Ginette Cecile Aasby, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 49 Valley View Dr, Sheridan, WY 82801 Phone: 417-459-8735 | |
Michelle Anne Eman, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 918 W Brundage Ln, Sheridan, WY 82801 Phone: 307-673-4420 |